Prostate-specific antigen and insulin-like growth factor binding protein-3 in nipple aspirate fluid are associated with breast cancer

Harris JR, Morrow M, Bonnadonna G. Cancer of the breast. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: J.B. Lippincott, 1993;1633–1726. Sauter, 1996, Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk, Cancer Epidemiol. Biomarkers Prev., 5, 967 Helle, 1996, Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients, Int. J. Cancer, 69, 335, 10.1002/(SICI)1097-0215(19960822)69:4<335::AID-IJC17>3.0.CO;2-4 Bruning, 1995, Insulin-like growth-factor-binding protein-3 is decreased in early-stage operable pre-menopausal breast cancer, Int. J. Cancer, 62, 266, 10.1002/ijc.2910620306 Baxter, 1993, Responses of insulin-like growth factor binding protein-1 (IGFBP-1) and the IGFBP-3 complex to administration of insulin-like growth factor-I, Acta Endocrinol. (Copenh), 128, 101, 10.1530/acta.0.1280101 Neely, 1992, Insulin-like growth factors (IGFs) reduce IGF-binding protein-4 (IGFBP- 4) concentration and stimulate IGFBP-3 independently of IGF receptors in human fibroblasts and epidermal cells, Endocrinology, 130, 985, 10.1210/en.130.2.985 Oh, 1995, Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells, Prog. Growth Factor Res., 6, 503, 10.1016/0955-2235(95)00025-9 Gill, 1997, Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner, J. Biol. Chem., 272, 25602, 10.1074/jbc.272.41.25602 Yu, 1998, Insulin-like growth factor-binding protein-3 and breast cancer survival, Int. J. Cancer, 79, 624, 10.1002/(SICI)1097-0215(19981218)79:6<624::AID-IJC12>3.0.CO;2-9 Rocha, 1996, Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features, J. Natl. Cancer Inst., 88, 601, 10.1093/jnci/88.9.601 Figueroa, 1993, Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status, J. Cell Biochem., 52, 196, 10.1002/jcb.240520211 Yu, 1994, Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age, Clin. Biochem., 27, 75, 10.1016/0009-9120(94)90015-9 Sauter, 1999, Biological markers of risk in nipple aspirate fluid are associated with residual cancer and tumour size, Br. J. Cancer, 81, 1222, 10.1038/sj.bjc.6690832 Okabe, 1999, The cleavage site specificity of human prostate-specific antigen for insulin-like growth factor binding protein-3, FEBS Lett., 447, 87, 10.1016/S0014-5793(99)00275-6 Lalou, 1993, Evidence that limited proteolysis of insulin-like growth factor binding protein-3 (IGFBP-3) occurs in the normal state outside of the bloodstream, Regul. Pept., 48, 179, 10.1016/0167-0115(93)90346-A Lee, 1994, Identification of insulin-like growth factor-binding protein-3 (IGFBP- 3) fragments and IGFBP-5 proteolytic activity in human seminal plasma: a comparison of normal and vasectomized patients, J. Clin. Endocrinol. Metab., 79, 1367, 10.1210/jc.79.5.1367 Lalou, 1996, Isolation and characterization of proteolytic fragments of insulin-like growth factor-binding protein-3, Horm. Res., 45, 156, 10.1159/000184779 Booth BA, Boes M, Dake BL, et al. Isolation and characterization of plasmin-generated bioactive fragments of IGFBP-3. Am J Physiol 1999;276(3 Part 1):E450–4. Black, 2000, Expression of a prostate-associated protein, human glandular kallikrein (hK2) in breast tumours and in normal breast secretions, Br. J. Cancer, 82, 361, 10.1054/bjoc.1999.0927 Agurs-Collins, 2000, Insulin-like growth factor-1 and breast cancer risk in postmenopausal African-American women, Cancer Detect Prev., 24, 199 Elmlinger, 1999, Limited proteolysis of the IGF binding protein-2 (IGFBP-2) by a specific serine protease activity in early breast milk, Pediatr. Res., 46, 76, 10.1203/00006450-199907000-00013 McCullagh P, Nelder JA. Generalized linear models. New York: Chapman & Hall, 1991. Keynes, 1923, Chronic mastitis, Br. J. Surg., 11, 89, 10.1002/bjs.1800114109 Petrakis, 1975, Association of race, age, menopausal status, and cerumen type with breast fluid secretion in nonlactating women, as determined by nipple aspiration, J. Natl. Cancer Inst., 54, 829 King, 1975, Cellular composition of the nipple aspirate specimen of breast fluid. I. The benign cells, Am. J. Clin. Pathol., 64, 728, 10.1093/ajcp/64.6.728 Hankinson, 1998, Circulating concentrations of insulin-like growth factor-I and risk of breast cancer, Lancet, 351, 1393, 10.1016/S0140-6736(97)10384-1 Yang, 1992, The distribution of PSA, cathepsin-D, and pS2 in BPH and cancer of the prostate, Prostate, 21, 201, 10.1002/pros.2990210304 Stege, 1999, Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy, Prostate, 38, 183, 10.1002/(SICI)1097-0045(19990215)38:3<183::AID-PROS2>3.0.CO;2-W Scanlon EF. Breast cancer. In: Holleb AI, Fink DJ, Murphy GP, editors. Textbook of clinical oncology. Atlanta: The American Cancer Society, 1991. p. 177–93. Mannello, 1999, Molecular forms and ultrastructural localization of prostate-specific antigen in nipple aspirate fluids, Clin. Chem., 45, 2263, 10.1093/clinchem/45.12.2263 Zhao, 2001, Nipple fluid carcinoembryonic antigen and prostate-specific antigen in cancer-bearing and tumor-free breasts, J. Clin. Oncol., 19, 1462, 10.1200/JCO.2001.19.5.1462